“Medical technology innovators continue to lead the way in solving some of the most pressing challenges facing patient care throughout the world, and it is critical that the United States remains the global leader in this dynamic industry,” said McCaulley. “MDMA has a tremendous track record of advancing policies that support this ecosystem, and I look forward to working with our members and all stakeholders who are committed to providing better health outcomes.”
McCaulley highlighted the importance of repealing the medical device tax to ensure it no longer thwarts patient care, shortening the gap between the regulatory process and securing reimbursement and negotiating a successful MDUFA reauthorization as some of his top priorities during the course of his chairmanship.
“Jeff recognizes how critical it is to protect and grow the innovative and entrepreneurial sector of the medical technology industry, and he will continue the proud tradition of leading MDMA’s passionate advocacy efforts,” said Mark Leahey, President and CEO of MDMA.
McCaulley follows the successful three-year tenure of Paul LaViollete, Executive Chairman, SV Health Investors. McCaulley was named the Global President of DJO Surgical in 2017, and prior to that was President and CEO of Smiths Medical. Over his career, he also served as President of the Global Reconstructive Division at Zimmer, where he oversaw five global business units and numerous functions, and held several senior executive roles at GE Healthcare. McCaulley has a B.S. in Aerospace Engineering from the University of Cincinnati and an Executive MBA from the Owen Graduate School of Management at Vanderbilt University.
The election was held by the MDMA Board of Directors during a successful Annual Meeting in Washington, DC where over 150 medical technology executives heard from CMS Administrator Seema Verma, Principal Deputy Commissioner of FDA Amy Abernathy, CDRH Director Jeff Shuren and many more.